Skip to main content
2024 Guide to Patient Support Services

Clovis Oncology

2024 PSS Guide

Clovis Cares

Rubraca QuickStart Program

Clovis Oncology offers the Clovis Cares program to assist patients who have been prescribed Rubraca (Table).

Clovis Cares

Through the Clovis Cares program, patients can participate in the Rubraca $0 Co-pay Program, Rubraca QuickStart Program, Rubraca Patient Assistance Program, or the Rubraca Coverage Link Program. Clovis also offers the Clovis4You Text Support Program. To enroll your patient, visit https://clovis.iassist.com/.

Rubraca $0 Co-Pay Program

The Rubraca $0 Co-pay Program is for patients who have private or commercial insurance. Once enrolled, the Clovis Cares team will determine your patient’s eligibility for this and other Clovis Cares programs.

Rubraca QuickStart Program

The Clovis Cares QuickStart Program is for patients with government insurance. Once enrolled, the Clovis Cares team will determine your patient’s eligibility for this and other Clovis Cares programs.

Rubraca Patient Assistance Program

The Clovis Cares Patient Assistance Program is for patients with no insurance. Once enrolled, the Clovis Cares team will determine your patient’s eligibility for this and other Clovis Cares programs.

Rubraca Coverage Link Program

The Clovis Cares Coverage Link Program is for patients needing bridge coverage. Once enrolled, the Clovis Cares team will determine your patient’s eligibility for this and other Clovis Cares programs.

TABLE Clovis Oncology Drug

Drug
Indications
Patient support programs

Drug
Rubraca (rucaparib) tablets
Indications
Maintenance treatment of adults with a deleterious BRCA mutation (germline and/or somatic) associated with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy; treatment of adults with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.
Patient support programs